ArticlePrecision clinical medicine2019

A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance.

Ye Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.